Literature DB >> 16005384

Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.

Deanna M Barch1, Cameron S Carter.   

Abstract

BACKGROUND: Recent research on schizophrenia indicates that cognitive deficits in this illness are important predictors of functional outcome, highlighting the need for treatments that have a positive impact on cognitive function. Here we explore the hypothesis that acute administration of d-amphetamine can improve cognitive function in individuals with schizophrenia who are well-treated with typical antipsychotics, as well as in healthy controls performing under dual task conditions designed to elicit performance deficits analogous to those found in schizophrenia.
METHODS: Ten individuals with schizophrenia taking haldol or prolixin and 22 healthy controls performed spatial working memory, language production, and Stroop tasks under both placebo and 0.25 mg/kg of D-amphetamine.
RESULTS: D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia. In addition, D-amphetamine improved language production for both individuals with schizophrenia and controls.
CONCLUSIONS: These results provide support for the hypothesis that the adjunctive administration of dopamine agonist can improve cognitive in individuals with schizophrenia taking typical antipsychotics. The results are discussed in terms of their implications for understanding the nature of working memory deficits in schizophrenia, and potential future avenues for cognitive enhancement in this illness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005384     DOI: 10.1016/j.schres.2004.12.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  78 in total

Review 1.  Cognition in schizophrenia: core psychological and neural mechanisms.

Authors:  Deanna M Barch; Alan Ceaser
Journal:  Trends Cogn Sci       Date:  2011-12-12       Impact factor: 20.229

Review 2.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 3.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

4.  Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia.

Authors:  Dwight Dickinson; James M Gold
Journal:  Schizophr Bull       Date:  2007-08-16       Impact factor: 9.306

Review 5.  CNTRICS final task selection: executive control.

Authors:  Deanna M Barch; Todd S Braver; Cameron S Carter; Russell A Poldrack; Trevor W Robbins
Journal:  Schizophr Bull       Date:  2008-11-14       Impact factor: 9.306

6.  Lessons from MATRICS.

Authors:  Stephen R Marder
Journal:  Schizophr Bull       Date:  2011-02-16       Impact factor: 9.306

7.  Effects of MDMA, methamphetamine and methylphenidate on repeated acquisition and performance in rats.

Authors:  M Galizio; P McKinney; D T Cerutti; R C Pitts
Journal:  Pharmacol Biochem Behav       Date:  2009-09-19       Impact factor: 3.533

8.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

9.  The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats.

Authors:  Tracey Ko; John Evenden
Journal:  Psychopharmacology (Berl)       Date:  2008-09-30       Impact factor: 4.530

10.  Combined effects of acute stress and amphetamine on serial memory retrieval pattern in mice.

Authors:  Christophe Piérard; Christophe Tronche; Pierrette Liscia; Frédéric Chauveau; Daniel Béracochéa
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.